First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors.
Timothy Anthony YapAnthony W TolcherRuth PlummerJatinder Kaur MukkerMarta EnderlinChristine HickingThomas GrombacherGiuseppe LocatelliZoltan SzucsIoannis GounarisJohann S de BonoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Tuvusertib demonstrated manageable safety and exposure-related target engagement. Further clinical evaluation of tuvusertib is ongoing.